Use of Sorafenib in Two Metastatic Renal Cell Cancer Patients with End-Stage Renal Impairment Undergoing Replacement Hemodialysis
Elisa Ferraris(Fondazione Salvatore Maugeri), Camillo Porta(University of Pavia), Angioletta Lasagna(University of Pavia), Chiara Paglino, Pamela Di Cesare(Policlinico San Matteo Fondazione), Ilaria Imarisio(University of Pavia)
Cited by 17
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275